Patents by Inventor Neris Michel Enamorado Escalona

Neris Michel Enamorado Escalona has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-2 derivative polypeptides
    Patent number: 9206243
    Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 8, 2015
    Assignee: CENTRO DE IMMUNOLOGIA MOLECULAR
    Inventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodriguez, Neris Michel Enamorado Escalona, Agustin Bienvenido Lage Dávila
  • IL-2 DERIVATIVES POLYPEPTIDES WITH AGONIST ACTIVITY FOR THERAPY OF CANCER AND CHRONIC INFECTIONS
    Publication number: 20140314709
    Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptidess and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.
    Type: Application
    Filed: November 10, 2011
    Publication date: October 23, 2014
    Applicant: CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodríguez, Neris Michel Enamorado Escalona, Agustín Bienvenido Lage Dávila